Wells Fargo & Company MN decreased its holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 39.6% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 71,484 shares of the biopharmaceutical company’s stock after selling 46,880 shares during the quarter. Wells Fargo & Company MN owned 0.16% of Vanda Pharmaceuticals worth $1,165,000 as of its most recent filing with the SEC.

Several other large investors have also added to or reduced their stakes in the company. Rice Hall James & Associates LLC grew its stake in shares of Vanda Pharmaceuticals by 1.0% in the second quarter. Rice Hall James & Associates LLC now owns 27,903 shares of the biopharmaceutical company’s stock worth $455,000 after purchasing an additional 279 shares in the last quarter. American International Group Inc. grew its stake in shares of Vanda Pharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 22,563 shares of the biopharmaceutical company’s stock worth $316,000 after purchasing an additional 1,491 shares in the last quarter. Legal & General Group Plc grew its stake in shares of Vanda Pharmaceuticals by 37.4% in the second quarter. Legal & General Group Plc now owns 11,105 shares of the biopharmaceutical company’s stock worth $181,000 after purchasing an additional 3,022 shares in the last quarter. Teachers Advisors LLC grew its stake in shares of Vanda Pharmaceuticals by 1.0% in the first quarter. Teachers Advisors LLC now owns 535,861 shares of the biopharmaceutical company’s stock worth $7,502,000 after purchasing an additional 5,180 shares in the last quarter. Finally, Swiss National Bank boosted its stake in Vanda Pharmaceuticals by 9.6% during the second quarter. Swiss National Bank now owns 69,500 shares of the biopharmaceutical company’s stock valued at $1,133,000 after buying an additional 6,100 shares in the last quarter. 86.52% of the stock is owned by institutional investors.

Several research analysts recently weighed in on the company. BidaskClub cut Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. Zacks Investment Research raised Vanda Pharmaceuticals from a “sell” rating to a “strong-buy” rating and set a $18.00 target price for the company in a research note on Tuesday, August 8th. HC Wainwright set a $18.00 target price on Vanda Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, August 3rd. Piper Jaffray Companies set a $23.00 target price on Vanda Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, August 3rd. Finally, Oppenheimer Holdings, Inc. set a $21.00 target price on Vanda Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, August 3rd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $22.00.

ILLEGAL ACTIVITY WARNING: This news story was reported by Watch List News and is the property of of Watch List News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States and international trademark and copyright laws. The legal version of this news story can be viewed at https://www.watchlistnews.com/vanda-pharmaceuticals-inc-vnda-stake-lessened-by-wells-fargo-company-mn/1674775.html.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.18. Vanda Pharmaceuticals had a negative return on equity of 7.85% and a negative net margin of 6.54%. The business had revenue of $42.06 million during the quarter, compared to analysts’ expectations of $40.31 million. During the same period in the previous year, the firm earned $0.01 earnings per share. The firm’s quarterly revenue was up 16.7% compared to the same quarter last year.

Vanda Pharmaceuticals Profile

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Want to see what other hedge funds are holding VNDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vanda Pharmaceuticals Inc. (NASDAQ:VNDA).

Institutional Ownership by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.